AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Non-small cell lung carcinoma: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)NCT03456063 · results posted 2026-10-09 · Hoffmann-La Roche · 453 people · tests Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Placebo Comparator, Nab-pacl… A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerNCT03194893 · results posted 2026-10-09 · Hoffmann-La Roche · 50 people · tests Alectinib, Crizotinib Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerNCT04214262 · results posted 2026-10-06 · National Cancer Institute (NCI) · 417 people · tests Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18 Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCNCT02273375 · results posted 2026-09-14 · Canadian Cancer Trials Group · 1415 people · tests MEDI4736, Placebo Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyNCT04655976 · results posted 2026-07-01 · GlaxoSmithKline · 758 people · tests Cobolimab, Dostarlimab, Docetaxel Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT03088540 · results posted 2026-06-25 · Regeneron Pharmaceuticals · 712 people · tests Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based ChemotherapyNCT06267001 · results posted 2026-06-10 · Hoffmann-La Roche · 56 people · tests Atezolizumab, Tiragolumab, Placebo Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP StudyNCT03306992 · results posted 2026-06-09 · University of Utah · 182 people · tests Personalized Exercise Program A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerNCT04351555 · results posted 2026-06-05 · AstraZeneca · 358 people · tests Osimertinib, Cisplatin, Carboplatin, Placebo A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung CancerNCT04619797 · results posted 2026-06-03 · Hoffmann-La Roche · 542 people · tests Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)NCT04513925 · results posted 2026-06-03 · Hoffmann-La Roche · 829 people · tests Atezolizumab, Tiragolumab, Durvalumab Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLCNCT02504489 · results posted 2026-05-19 · BeyondSpring Pharmaceuticals Inc. · 559 people · tests Docetaxel + Plinabulin (DP), Docetaxel (D)
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.J Clin Oncol 2026 · PMID 42928710 Cardiovascular resilience in centenarians.Nat Rev Cardiol 2026 · PMID 42928381 ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.Nature 2026 · PMID 42927884 Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 …Ann Oncol 2026 · PMID 42927858 From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology's New Pillar.Ann Oncol 2026 · PMID 42927857 Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label…Ann Oncol 2026 · PMID 42927856 Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carc…Ann Oncol 2026 · PMID 42927855 Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE rando…Ann Oncol 2026 · PMID 42927854 A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Re…Ann Oncol 2026 · PMID 42927853 Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer …Lancet Oncol 2026 · PMID 42927765 Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.Nat Med 2026 · PMID 42926233 Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136
🏛️

US drug labels updated

A label changes when a new use, dose or warning is approved · openFDA

No label updates found.

An update is not always a new approval — open the label to see what changed.

Want these every week? Follow non-small cell lung carcinoma and get a note on your phone with the new trials and papers.

🔔 Follow non-small cell lung carcinoma
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy